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Aims To evaluate myocardial flow reserve (MFR) and coronary artery calcium (CAC) in persons with Type 1 diabetes
with or without albuminuria and in non-diabetic controls. MFR reflects the function of large epicardial arteries and
myocardial microcirculation. CAC represents structural aspects of atherosclerosis. In addition, we evaluated the as-
sociation of MFR and CAC with retinopathy, another microvascular complication.
...................................................................................................................................................................................................
Methods
and results
Cross-sectional study in Type 1 diabetes, stratified by normoalbuminuria (NORMO; n= 30) and macroalbuminuria
(MACRO; n= 30), and in non-diabetic controls (n= 30). MFR (pharmacological stress flow/rest flow) was evaluated
by cardiac 82Rb positron emission tomography/computed tomography. MFR was similar in patients with NORMO
and controls (3.1 ± 0.79 vs. 3.0 ± 0.79; P= 0.74). Patients with MACRO had lower (impaired) MFR when compared
with NORMO (2.1 ± 0.92 vs. 3.1 ± 0.79; P< 0.0001). The CAC score [median (interquartile range)] was higher in
NORMO when compared with controls [72 (22–247) vs. 0 (0–81), P= 0.03], and comparable between MACRO
and NORMO. MFR was comparable in patients with diabetes and simplex or no retinopathy (n= 24 and n= 12,
2.8 ± 0.84 vs. 3.3 ± 0.77, P= 0.11), but lower in proliferative (n= 24) compared with simplex retinopathy (2.1 ± 0.97
vs. 2.8 ± 0.84, P= 0.02). The CAC score was comparable between groups of retinopathy.
...................................................................................................................................................................................................
Conclusion Myocardial microvascular function was comparable in non-diabetic controls and patients with Type 1 diabetes and
NORMO; but impaired in the presence of microvascular complications (MACRO and proliferative retinopathy).
Coronary calcification was elevated in diabetes, however, not explained by albuminuria.
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Introduction
Approximately 35% of persons with Type 1 diabetes will develop al-
buminuria. Deckert et al.1 proposed in 1989 in the Steno hypothesis
that albuminuria reflects widespread vascular damage. The hypoth-
esis links leaky renal vessels to a general impaired vascular endothelial
function. Many subsequent studies have confirmed the association
between albuminuria, retinopathy, and risk of cardiovascular dis-
ease2,3 supporting the hypothesis of widespread vascular damage in
Type 1 diabetes.
Major advances in non-invasive imaging enable the investigation of
new aspects of the microcirculation. Among these methods is
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quantitative cardiac positron emission tomography (PET) which
allows the measurement of myocardial blood flow at rest and during
pharmacologically induced hyperaemic conditions. The ratio be-
tween resting and maximal induced myocardial blood flow is termed
the myocardial flow reserve (MFR) and reflects to what extend the
flow can increase during stress. MFR mirrors the function of the large
epicardial arteries and the microcirculation of the myocardium.4 A
hybrid scanner can combine cardiac PET with computed tomography
(CT) to estimate coronary artery calcium (CAC), a specific marker of
atherosclerosis.
Knowledge about cardiac microvascular function in Type 1 dia-
betes is scarce. Only two small studies have reported impaired MFR
in young men with Type 1 diabetes as compared to healthy
controls.5,6
In a recent study in persons with Type 2 diabetes free of overt car-
diovascular disease, we demonstrated lower (impaired) MFR and
higher CAC score (increased calcification) to be associated with con-
comitant albuminuria.7 It is not clear to what extent these findings
can be extrapolated to Type 1 diabetes.
Taking advantages of similar cardiac PET/CT imaging as in our
study of persons with Type 2 diabetes, we undertook a cross-
sectional study in healthy controls and persons with Type 1 diabetes
stratified by albumin excretion. We aimed to gain information of the
prevalence and predictors of reduced MFR and increased CAC in
persons with Type 1 diabetes (with or without albuminuria) while
comparing them to non-diabetic controls, and in addition, we eval-
uated the association of MFR and CAC with diabetic retinopathy, an-
other microvascular complication.
Methods
Study population
We included 60 persons with Type 1 diabetes according to the WHO
criteria. A priori, we decided to include 30 participants with normoalbu-
minuria (NORMO) (<30 mg/24 h or 30 mg/g creatinine) and 30 partici-
pants with a history of macroalbuminuria (MACRO) (>_300 mg/24 h or
300 mg/g creatinine in two out of three consecutive urine collections;
n= 30). Persons with NORMO and MACRO were matched on age and
sex. Persons classified with NORMO did not have any history of microal-
buminuria or MACRO prior to enrolment in the study. The participants
were recruited from the Steno Diabetes Center Copenhagen among
subjects participating in a cross-sectional study focusing on detailed phe-
notyping of Type 1 diabetes patients with or without progressive renal
complications. None of the participants included were symptomatic for
angina and the reason of the cardiac PET/CT was exclusively research.
Exclusion criteria were (i) non-diabetic kidney disease; (ii) renal failure
[estimated glomerular filtration rate (eGFR) <15 mL/min/1.73 m2], dialy-
sis, or kidney transplantation; (iii) change in renin–angiotensin aldoster-
one system blocking treatment during the last month; and (iv)
contraindications for cardiac PET/CT. Moreover, 30 healthy non-diabetic
persons studied earlier with an identical protocol using the same equip-
ment at our centre in 20137 were used as controls.
Power calculation was performed using the power statement imple-
mented in the SAS software, version 9.3. Calculations were based on our
previous results on MFR in persons with Type 2 diabetes performed in
the same centre using the same equipment.7 In the assumption of a mean
difference in MFR of 0.6 [and a standard deviation (SD) of 0.8] between
persons with NORMO vs. MACRO, a total of 54 persons (27 in each
group) were needed to provide 80% power for a Type 1 error of 5%.
We included 30 persons in each group to account for technical difficulties
and incomplete investigations.
The study was performed from August 2016 to January 2018. The
study was conducted in accordance with the Helsinki protocol and all
participants gave informed written consent and the protocol was
approved by the local ethics committee.
Clinical measurements
HbA1c was measured by high performance liquid chromatography. Plasma
creatinine was measured by an enzymatic method (Hitachi 912, Roche
Diagnostics, Mannheim, Germany). The CKD-EPI equation was used to
calculate eGFR.8 Urinary albumin creatinine rate (UACR) was measured
by an enzyme immunoassay in three consecutive morning urine samples.
Measurements of 24-h blood pressure were recorded using a cuff-device
(Takeda, TM2430, Japan9) programmed to measure blood pressure every
15 min between 7 am and 10 pm and every 30 min between 10 pm and
7 am. Standard resting 12-lead electrocardiogram was obtained. Height
and weight was measured, and body mass index was calculated as weight/
height (kg/m2). A detailed medical history including treatment and previ-
ous cardiovascular disease was obtained from all participants and cross
referenced with electronic patient records. Current smoking was defined
as one or more cigarettes/cigars/pipes a day.
For the control subjects, all clinical measurements were assessed and
defined as described above with the exceptions that (i) urinary albumin
excretion rate (UAER) was measured in two 24-h urine collections by an
enzyme immunoassay; and (ii) 24-h blood pressure was recorded using
BPro (HealthStats, Singapore), a tonometric wrist-device that records
brachial blood pressure derived from radial pulse waves.10 The device
captured the blood pressure every 15 min for 24 h.
Hybrid cardiac PET/CT imaging
A dynamic, gated cardiac PET/CT study was performed using a hybrid
PET/CT scanner in 3D mode (Siemens Biograph mCT 128, Siemens,
Munich, Germany) after administration of 1100 MBq 82Rb (CardioGen-
82, Bracco Diagnostics, Monroe Township, NJ, USA). The procedure has
previously been described in detail.7 Cardiac PET/CT was performed at
rest and at stress after adenosine was infused at 140mg/kg/min for 6 min
to induce maximum myocardial hyperaemia. Myocardial blood flow was
automatically calculated using the Siemens Syngo MBF 2.3 (Siemens
Medical Solutions, Malvern, PA, USA) with one-compartment tracer kin-
etic models for 82Rb11 and the extraction curve from Lortie et al.12
Myocardial perfusion abnormalities were assessed semi quantitative by
two experienced operators. Before the examination, phosphodiesterase
5 inhibitors were discontinued for 72 h, dipyridamole-containing medica-
tions were discontinued for 36 h, and nitrates were discontinued for 12 h.
Moreover, all subjects refrained from caffeine-containing beverages for
18 h before examination, and theophylline-containing medications were
discontinued for 24 h. Angiotensin converting enzyme inhibitors were
not discontinued,13,14 and we did not set therapy with beta-blocker on
hold due to possible discomfort for the patients and it has been demon-
strated that beta-blocker can be continued without loss of the essential
interpretation of the results.15 CAC score was calculated as the sum of
CAC content in the three main coronary arteries using the method
described by Agatston et al.16 and semiautomated commercially available
software (Corridor4DM, INVIA, Ann Arbor, MI, USA).
Different cut-off for MFR has been applied depending on the charac-
teristic of the study population; and a cut-off of 2.5 has been suggested in
patients without obstructive coronary artery disease (CAD).17,18 We,
therefore, prespecified a cut-off of 2.5. An elevated CAC was defined as
an Agatston score >300.19
MFR assessed by cardiac 82Rb PET/CT 797
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Retinopathy
Retinopathy status was obtained from medical records for the diabetic
participants. All persons attending the outpatient clinic at Steno Diabetes
Center Copenhagen have regular ophthalmology examinations (approxi-
mately every 1–2 years) where retinal photographies are taken through a
dilated pupil by certified eye nurses. Retinopathy was graded as nil, pres-
ence of or historical simplex, proliferative, or blind based on the worst
eye.
Statistical analysis
For continuous variables, the normal distributed are given as mean and
SD, and the non-normal distributed (CAC, UACR, and alcohol intake) as
median with interquartile range (IQR). Categorical variables are provided
as total numbers in percent. When analysing differences between two
groups, we applied independent samples t-test when comparing continu-
ous variables, and the v2 test or Fisher’s exact test as appropriate when
comparing categorical variables. The non-normal distributed variables
were log2 transformed in all analyses. However, the CAC score distribu-
tion was highly skewed and hence not amenable to transform into normal
distribution and was analysed using the Mann–WhitneyU test. When ana-
lyzing differences in MFR and CAC in adjusted analysis, analysis of covari-
ance was applied, ensuring normal distribution of the residuals for CAC
after log2 transformation. Linear regression was used to analyse correla-
tions between MFR, CAC, and other covariates. We provide R2 to pre-
sent the proportion of variability in the dependent variable explained by
the model and the F-test was applied to determine whether this relation-
ship was statistically significant.
Participants with a history of percutaneous coronary intervention
(n= 5) were excluded from the analyses of CAC. Results were consid-
ered to be significant at a two-tailed P-value <0.05. Statistical analyses
were performed using SAS software (version 9.3; SAS Institute).
Rationale for selection of covariates
We adjusted for traditional cardiovascular risk factors based on prior evi-
dence. In analysis comparing the level of MFR and CAC between con-
trols, patients with diabetes and NORMO or MACRO we adjusted for
sex, age, 24-h systolic blood pressure, eGFR, and smoking. The groups
were pre-categorized according to UACR, HbA1c, and diabetes duration
and these covariates were therefore omitted as was medical treatment
due to risk of bias by indication. We did not adjust for low density lipo-
protein (LDL) cholesterol, since the level was higher in controls when
compared with the diabetic participants most likely because the controls
were not receiving lipid-lowering treatment. In analyses restricted to the
participants with diabetes, we applied additionally adjustment for HbA1c,
LDL cholesterol and diabetes duration, and for the analyses of retinop-
athy also for UACR.
Results
Clinical characteristics
Characteristics for the total cohort are presented in Table 1. The 90
participants included 37 (41%) females and mean ± SD age was
59.3 ± 9.5 years. Compared to the persons with NORMO the
....................................................................................................................................................................................................................
Table 1 Clinical characteristics of participants
Characteristics Controls
(n5 30)
Normoalbuminuria
(n5 30)
Macroalbuminuria
(n530)
P-value
controls vs.
normoalbuminuria
P-value
normoalbuminuria
vs. macroalbuminuria
Female (%) 40 40 43 1.0 0.79
Age (years) 59.8 ± 9.9 59.8 ± 9.1 58.2 ± 9.9 0.99 0.52
Known diabetes duration (years) 32.6 ± 12.7 41.4 ± 13.3 0.01
Body mass index (kg/m2) 24.7 ± 3.4 25.6 ± 4.1 27.2 ± 4.2 0.38 0.15
HbA1c (mmol/mol) 35.8 ± 1.9 61.3 ± 8.3 66.3 ± 11.7 <0.0001 0.70
HbA1c (%) 5.4 ± 0.17 7.8 ± 0.76 8.2 ± 1.07 <0.0001 0.70
LDL cholesterol (mmol/L) 3.4 ± 0.7 2.3 ± 0.7 2.1 ± 0.8 <0.0001 0.32
Total cholesterol (mmol/L) 5.5 ± 0.7 4.5 ± 0.8 4.4 ± 0.9 <0.0001 0.73
eGFR (mLmin-1 1.73m-2) 82.8 ± 13.1 89.1 ± 10.4 62.5 ± 23.1 0.043 <0.0001
Urinary albumin creatinine rate (mg/g)a 6 (5–10.5) 3 (3–5) 121 (53–283) 0.0002 <0.0001
Smokers (%) 13 14 14 0.96 1.0
Alcohol (beverages/week) 8.5 (4–14) 7 (4–18) 6.5 (1–14) 0.87 0.91
Antihypertensive treatment (%) 10 57 100 0.0001 <0.0001
RAAS inhibition treatment (%) 10 47 97 0.002 <0.0001
Beta-blocker treatment (%) 0 3 27 1.0 0.026
Aspirin treatment (%) 3 37 63 0.0012 0.039
Lipid-lowering treatment (%) 0 70 80 <0.0001 0.37
Retinopathy (no/simplex/proliferative) (%) 37/53/10 3/27/70
Known coronary artery disease (%) 0 0 12 0.01
Data are expressed as n (%), mean ± SD, or geometric mean (IQR). P values from independent samples t-test and v2 test or Fisher’s exact test.
eGFR, estimated glomerular filtration rate; RAAS, renin–angiotensin aldosterone system.
aUrinary albumin excretion rate (mg/24 h) for the 30 controls.
798 E.H. Zobel et al.
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controls had lower 24-h systolic blood pressure, HbA1c, and eGFR
but higher LDL cholesterol and UACR. Persons with MACRO had
longer diabetes duration and lower eGFR compared with persons
with NORMO. Of the 60 participants with diabetes, 7 (12%) had
known CAD (five had a history of percutaneous coronary interven-
tion and two had coronary artery bypass graft). These participants
were all in the group with MACRO. Simplex retinopathy was present
in 16 (53%) and proliferative retinopathy in 3 (10%) of the persons
with NORMO. Simplex retinopathy was present in 8 (27%) and pro-
liferative retinopathy in 21 (70%) of the persons with MACRO. In the
total population, the mean left ventricular ejection fraction at rest
was 64.2% with a range of 39–85%.
Cardiac PET/CT in controls and in Type 1
diabetes stratified by urinary albumin
excretion
The MFR and the frequency of reduced MFR (<2.5) were similar in
persons with NORMO and in controls (3.1 ± 0.79 vs. 3.0± 0.79 and
23 vs. 17%, P>_ 0.52). Persons with MACRO had a lower MFR and
the frequency of reduced MFR was higher when compared with per-
sons with NORMO (2.1 ± 0.92 vs. 3.1± 0.79 and 77 vs. 23%,
P< 0.0001). When we adjusted the MFR for CAC score, MFR
remained lower and the frequency of reduced MFR higher in persons
with MACRO compared to NORMO (P<_ 0.001).
The CAC score was higher in persons with NORMO compared
to controls [72 (22–247) vs. 0 (0–81), P= 0.028], and comparable be-
tween persons with MACRO and NORMO [263 (23–1315) vs. 72
(22–247), P= 0.17]. The frequency of high CAC was similar in per-
sons with NORMO and the controls (17 vs. 7%, P= 0.71), but higher
in persons with MACRO compared to NORMO (44 vs. 17%,
P= 0.026). Results are summarized in Table 2.
After adjustment for sex, age, 24-h systolic blood pressure, eGFR,
and smoking, MFR remained lower and the frequency of reduced
MFR higher in persons with MACRO compared to NORMO
(P<_ 0.0077, Figure 1A), and these differences persisted after additional
adjustment for HbA1c, LDL cholesterol, and diabetes duration
(P<_ 0.038). The CAC remained higher in the persons with NORMO
compared to controls after adjustment (P= 0.03), but the difference
between persons with MACRO and NORMO lost significance.
The myocardial blood flow during stress were similar in persons
with NORMO and in controls (3.0± 0.51 vs. 3.0 ± 0.53 mL/g/min,
P= 0.73). Persons with MACRO had lower myocardial blood flow
during stress compared with persons with NORMO (2.5± 0.82 vs.
3.0± 0.51 mL/g/min, P= 0.004). Results are summarized in Table 2.
....................................................................................................................................................................................................................
Table 2 Cardiac PET/CTand albuminuria
Variables Controls
(n5 30)
Normoalbuminuria
(n5 30)
Macroalbuminuria
(n5 30)
P-value
controls vs.
normoalbuminuria
P-value
normoalbuminuria vs.
macroalbuminuria
24-h systolic blood pressure (mmHg) 127 ± 13 135 ± 9 138 ± 11 0.009 0.26
24-h diastolic blood pressure (mmHg) 79 ± 8 78 ± 6 77 ± 5 0.88 0.48
24-h pulse pressure (mmHg) 48 ± 10 57 ± 6 61 ± 9 0.0002 0.04
Heart rate (bpm) 61 ± 8 69 ± 12 72 ± 12 0.003 0.41
Myocardial blood flow rest (mL/g/min) 1.1 ± 0.25 1.0 ± 0.25 1.2 ± 0.35 0.82 0.01
Myocardial blood flow stress (mL/g/min) 3.0 ± 0.53 3.0 ± 0.51 2.5 ± 0.82 0.73 0.004
MFR 3.0 ± 0.79 3.1 ± 0.79 2.1 ± 0.92 0.74 <0.0001
MFR <2.5 (%) 17 23 77 0.52 <0.0001
CAC scorea 0 (0–81) 72 (22–247) 263 (23–1315) 0.028 0.17
CAC score >300 (%) 7 17 44 0.71 0.026
Data are expressed as total numbers in percent, mean ± SD, or geometric mean (IQR). P-values from independent samples t-test, v2test, and Mann–Whitney U testa or Fisher’s
exact test.
CAC, coronary artery calcium; MFR, myocardial flow reserve.
A
B
Figure 1 Estimated marginal means with 95% CIs for myocardial
flow reserve (MFR) adjusted for sex, age, 24-h systolic blood pres-
sure, eGFR, and smoking according to groups [(A) Controls, nor-
moalbuminuria and macroalbuminuria; (B) Retinopathy].
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The difference between persons with MACRO and NORMO lost
significance following adjustment (P= 0.19).
A total of 10 participants had ischaemia on the PET/CT, seven of
which were known with CAD. All 10 had reversible ischaemia (Nine
with MACRO and one healthy control), median (IQR) extent was 24
(14–29)%. In five of these participants, irreversible ischaemia (fixed
perfusions defects) was also observed, all had MACRO and the me-
dian extent was 19 (16–25)%.
Cardiac PET/CT in persons with Type 1
diabetes stratified by retinopathy stage
In persons with simplex retinopathy (n= 24) compared to persons
without retinopathy (n= 12) MFR was comparable (2.8± 0.84 vs.
3.3 ± 0.77, P= 0.11), while reduced MFR was more frequent (46 vs.
8%, P= 0.03). In persons with proliferative (n= 24) compared to sim-
plex retinopathy the MFR was lower (2.1± 0.97 vs 2.8± 0.84,
P= 0.02) and the frequency of reduced MFR was higher (75 vs. 46%,
P= 0.04). The CAC score was comparable between stages of retin-
opathy, but high CAC was more frequent in persons with prolifera-
tive compared to simplex retinopathy (48 vs. 14%, P= 0.04). Results
are summarized in Table 3.
The MFR remained lower in persons with proliferative compared
to simplex retinopathy after initial adjustment (P= 0.03, Figure 1B),
but lost significance after further adjustment for HbA1c, LDL choles-
terol, diabetes duration, and UACR (P= 0.27). The differences in fre-
quency of reduced MFR and high CAC between retinopathy groups
lost significance after adjustment.
Variables correlated with MFR and CAC
In the total population, MFR was negatively correlated with CAC
(R2 = 0.20, P< 0.0001, Figure 2A), UACR (R2 = 0.25, P< 0.0001,
Figure 2B), age (R2 = 0.07, P= 0.01), 24-h systolic blood pressure
(R2 = 0.05, P= 0.04), and positively correlated with eGFR (R2 = 0.22,
P< 0.0001, Figure 2C). In analyses restricted to the persons with dia-
betes, MFR was negatively correlated with CAC (R2 = 0.15,
P= 0.004), UACR (R2 = 0.25, P< 0.0001), age (R2 = 0.07, P= 0.04),
and diabetes duration (R2 = 0.19, P= 0.0005), and positively corre-
lated with eGFR (R2 = 0.22, P= 0.0002).
In the total population, CAC was negatively correlated with eGFR
(R2 = 0.06, P= 0.02) and positively correlated with UACR (R2 = 0.05,
P= 0.04), age (R2 = 0.21, P< 0.0001), and 24-h systolic blood pressure
(R2 = 0.10, P= 0.004). In the diabetic population, CAC was positively
correlated with age (R2 = 0.30, P< 0.0001) and diabetes duration
(R2 = 0.17, P= 0.002) but not UACR (R2 = 0.009, P= 0.50).
....................................................................................................................................................................................................................
Table 3 Cardiac PET/CTand retinopathy
Variables No retinopathy
(n5 12)
Simplex
(n524)
Proliferative
(n5 24)
P-value no
retinopathy
vs. simplex
P-value simplex
vs. proliferative
MFR 3.3 ± 0.77 2.8 ± 0.84 2.1 ± 0.97 0.11 0.02
MFR <2.5 (%) 8 46 75 0.03 0.04
CAC scorea 45 (0–435) 72 (23–247) 299 (51–1651) 0.42 0.25
CAC score >300 (%) 25 14 48 0.64 0.04
Data are expressed as total numbers in percent, mean ± SD, or geometric mean (IQR). P-values from independent samples t-test, v2test, and Mann–Whitney U testa or Fisher’s
exact test.
CAC, coronary artery calcium; MFR, myocardial flow reserve.
A
B
C
P
P
P
Figure 2 Correlations between myocardial flow reserve (MFR)
and (A) coronary artery calcium, (B) urinary albumin creatinine ratio
(UACR) and (C) estimated glomerular filtration rate (eGFR).
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Variables association with MFR in
adjusted analyses
In the total cohort, higher UACR (P= 0.02), higher age (P= 0.009),
lower eGFR (P= 0.03), and smoking (P= 0.02) were associated with
lower MFR in multivariate linear regression (R2 = 0.39). In analyses
restricted to the persons with diabetes, higher UACR (P= 0.02), fe-
male sex (P= 0.02), higher age (P= 0.05), and longer diabetes dur-
ation (P= 0.02) were independently associated with lower MFR
(R2 = 0.54).
Variables association with CAC in
adjusted analysis
Higher age and 24-h systolic blood pressure were associated with
higher CAC in multivariate linear regression (R2 = 0.34) in the total
cohort (P<_ 0.03). Further inclusion of MFR added to the model
(R2 = 0.41) and was significantly associated with higher CAC
(P= 0.004). In analyses restricted to the persons with diabetes, longer
diabetes duration (P= 0.03) and higher age (P= 0.0002) were associ-
ated with higher CAC (R2 = 0.44). Further inclusion of MFR added to
the model (R2 = 0.46), but was not significantly associated with CAC
(P= 0.22).
Additional analysis
To avoid the potential confounding effect of epicardial stenosis on
MFR, we performed a sensitivity analysis excluding all participants
with known CAD or reversible and/or irreversible ischaemia
revealed by cardiac PET (n= 10). MFR was 3.0± 0.79; 3.1± 0.79, and
2.3 ± 0.89 in controls, in persons with NORMO, and in persons with
MACRO, respectively. These results are presented in Supplementary
data online, Table S1. The results were confirmatory as the differences
in MFR and in MFR <2.5 between normoalbuminuric participants
and controls were non-significant, and the differences between
macroalbuminuric and normoalbuminuric participants were signifi-
cant (P<_ 0.002). After adjustment for sex, age, 24-h systolic blood
pressure, eGFR, and smoking, MFR remained lower and the fre-
quency of reduced MFR higher in persons with MACRO compared
to NORMO (P<_ 0.03). After additional adjustment for HbA1c, LDL
cholesterol, and diabetes duration, the difference in MFR lost signifi-
cance (P= 0.10), however, the difference in reduced MFR (<2.5)
persisted (P= 0.007).
Discussion
The main findings in this study were (i) the myocardial microvascular
function was comparable in the healthy controls and the persons
with Type 1 diabetes and NORMO; but impaired in the presence of
MACRO and also in the presence of another microvascular compli-
cation: retinopathy; (ii) the coronary calcification was high in persons
with Type 1 diabetes, but was to a larger extent explained by age and
diabetes duration than presence of albuminuria. Our findings signify
that microvascular impairment occurs in multiple microvascular beds
and we detected microvascular injury in the heart which potentially
affects how heart disease in Type 1 diabetes should be understood
and treated.
Very little data on myocardial blood flow in Type 1 diabetes has
been published until now. Older studies in a limited number of dia-
betic persons (mix of Types 1 and 2) referred for coronary arterio-
graphy have shown reduced MFR in persons with diabetes compared
to persons without diabetes.20–22 The ability to measure MFR non-
invasively by cardiac PET allows examinations of larger and less
selected populations. In 2783 consecutive patients referred for car-
diac PET Murthy et al.23 demonstrated that the rate of cardiac death
for the diabetes patients (n= 1172, type of diabetes not specified)
without CAD but with impaired MFR was comparable to that for
non-diabetic patients with CAD. The cardiac mortality rate for per-
sons with diabetes but without CAD and preserved MFR was very
low. This emphasizes impaired MFR as a powerful, independent pre-
dictor of cardiac death in diabetes.
In this study by Murthy et al., the patients had symptoms of chest
pain and/or dyspnoea and more than 60% had previous cardiovascu-
lar disease. Therefore, the median values for MFR was very low (1.6
for the patients with diabetes and 1.9 for the non-diabetics) and the
cut-off for impaired MFR was chosen accordingly. In our population,
we anticipated that the prevalence of cardiovascular disease was con-
siderable lower, and therefore, that the median MFR was higher. In
accordance with our expectations, the median value for MFR was 2.7
in our study.
Knowledge about the myocardial microvascular function in Type 1
diabetes is sparse. Our study showed that myocardial microvascular
function was comparable in the healthy controls and the persons
with Type 1 diabetes and NORMO. Pitka¨nen et al.6 reported
impaired MFR quantified by cardiac PET in 12 young men with Type 1
diabetes and NORMO compared with 12 healthy matched volun-
teers (3.76± 1.69 vs. 5.31 ± 1.86, P< 0.05). Similarly, a study including
35 young subjects with diabetes (18 with Type 1 and 17 with Type 2)
and 11 age-matched healthy controls, showed that the MFR was
comparable in the subjects with Type 1 and Type 2 diabetes, but
lower than in the controls.24 In comparison, our study population
consisted of older patients with a longer duration of diabetes, which
may account in part for the different results.
In our study, myocardial microvascular function was impaired in
the presence of MACRO and this association persisted after adjust-
ment for traditional cardiovascular risk factors including the variables
associated with lower MFR in our cohort (higher UACR, female sex,
higher age, and longer duration of diabetes). MFR may capture both
epicardial artery disease as well as microvascular disease. When we
used CAC score as a co-variate (in absence of direct athero-
quantification such as CT-angiogram-derived plaque burden) to test
whether there was a true difference in microvascular disease be-
tween the participants with MACRO compared to NORMO, MFR
remained lower and the frequency of reduced MFR higher in persons
with MACRO compared to NORMO. To further disentangle if the
association between albuminuria and MFR simply reflected existing
clinically diagnosed CAD, we performed a separate set of analysis
excluding the 10 participants with known CAD and/or ischaemia
revealed by cardiac PET/CT. Our results were confirmatory indicat-
ing that there is a separate microvascular injury in the heart in Type 1
MFR assessed by cardiac 82Rb PET/CT 801
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diabetes and it is found especially in the persons with further micro-
vascular damage. Our findings in Type 1 diabetes are concordant
with results from a study published in 2004 that demonstrated
impaired MFR, measured by cardiac PET, in 16 persons with Type 1
diabetes with microangiopathy as compared to 12 without (P< 0.05).
Microangiopathy was defined as presence of non-proliferative diabet-
ic retinopathy (n= 14), microalbuminuria (n= 2), and/or peripheral
neuropathy (n= 10).25 We have previously reported impaired MFR
in persons with Type 2 diabetes and albuminuria (UAER >_30 mg/
24 h, n= 30) as compared to NORMO (n= 30).7 Recently, these
results have been confirmed in a larger study including 118 patients
with Type 2 diabetes demonstrating that MFR decreased progressive-
ly in relation to higher urinary albumin excretion.26
Knowledge about the myocardial microvascular function in Type 1
diabetes and the link to retinopathy is also limited. A cardiac PET
study in 21 young men with Type 1 diabetes and NORMO found no
difference in MFR in participants with or without retinopathy nor
between patients with diabetes without retinopathy and 12 non-
diabetic controls (P>_ 0.2).5 Comparable results were shown in an-
other small study including 12 young men with Type 1 diabetes and
NORMO; here, MFR was similar in the presence of mild background
retinopathy (n= 5) as in patients without retinopathy.6 However,
these results are in contrast to a small study (n= 29) in Type 2 dia-
betes demonstrating reduced MFR, measured by cardiac catheteriza-
tion, in the presence of retinopathy compared with no retinopathy
(1.9 ± 0.4 vs. 2.8± 0.3, P< 0.01). Data on renal function or albumin
excretion were not presented.27 We demonstrated an association
between impaired microcirculation in the heart and proliferative ret-
inopathy. In contrast to the two small studies in young men with
Type 1 diabetes, our study population was larger, older, and with lon-
ger diabetes duration.
Since diabetic retinal disease often coexists with diabetic renal dis-
ease, it has been difficult to discern their individual association to car-
diovascular disease in Type 1 diabetes. Our study was intentionally
stratified by albuminuria and the association between MFR and retin-
opathy was partly explained by the albumin excretion rate, signifying
that retinopathy had no independent association to the myocardial
microcirculation. Ninety-seven percent of the persons with MACRO
in our study had retinopathy underlining the close relation between
retinal and renal disease in Type 1 diabetes.
CAC is an accepted non-invasive measure of atherosclerotic bur-
den. Our findings of higher CAC in people with Type 1 diabetes than
in non-diabetic control subjects are in concordance with the results
from the Coronary Artery Calcification in Type 1 Diabetes Study.28
We report comparable CAC score between persons with MACRO
and NORMO, however, investigating the association dichotomized
at a CAC score >300, we found a higher frequency of elevated CAC
score in persons with MACRO compared to NORMO. It may be
that there is an association between CAC and albuminuria in Type 1
diabetes, but we might have limited power to detect it because of the
skewed distribution of CAC scores.
Clinical implications
Our findings suggest microvascular myocardial damage is common in
Type 1 patients and can be identified with MACRO. How best to
treat the microvascular damage in the heart remains to be established
in future studies in contrast to the macrovascular damage known to
respond to antihypertensive and lipid-lowering medication.
Strengths and limitations
The strength of this study is that to our knowledge this is the first
evaluation of MFR and CAC in Type 1 diabetes in a cohort stratified
by albuminuria by design. Potential limitations include that (i) the
power calculation was based on differences in MFR between albumi-
nuric groups and not retinopathy; and (ii) the cross-sectional nature
of our study precludes the assessment of causal relationships.
Conclusion
In persons with Type 1 diabetes, we have demonstrated (i) impaired
MFR in persons with MACRO compared to NORMO; and (ii)
impaired MFR in persons with proliferative compared to simplex ret-
inopathy. Our findings support the hypothesis that albuminuria
reflects widespread vascular damage in Type 1 diabetes and that
microvascular impairment occurs in multiple microvascular beds.
Prospective studies are needed to establish the role of MFR in cardio-
vascular disease risk prediction in Type 1 diabetes.
Supplementary data
Supplementary data are available at European Heart Journal - Cardiovascular
Imaging online.
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